Literature DB >> 20235611

Modulation of cell surface expression of nonactivated cholecystokinin receptors using bivalent ligand-induced internalization.

Kaleeckal G Harikumar1, Eyup Akgün, Philip S Portoghese, Laurence J Miller.   

Abstract

CCK(2) receptor antagonists potentiate pain relief by MOP receptor agonists. In an attempt to enhance this effect, we prepared bivalent ligands incorporating CCK(2) receptor antagonist and MOP receptor agonist pharmacophores. (9) Ligands with 16- to 22-atom spacers could simultaneously bind both receptors but provided no advantage in activity over individual ligands. We now examine the effect of these ligands on receptor internalization as a mechanism of receptor regulation. We prepared CHO cell lines expressing nonfluorescent halves (YN and YC) of yellow fluorescent protein attached to each receptor. Spatial approximation of constructs was needed to yield fluorescence. Monovalent MOP agonist 1 signaled normally and internalized the MOP receptor. Monovalent CCK(2) antagonist 2 did not stimulate receptor internalization. In the dual receptor-bearing cells, bivalent ligands 3a-c capable of simultaneously binding both receptors resulted in cell surface fluorescence and internalization of the fluorescent complex in a time- and temperature-dependent manner. Bivalent ligand 4 with spacer too short to occupy both receptors simultaneously yielded no signal. Receptor tethering with appropriate bivalent ligands can down-regulate signaling by moving a nonactivated receptor into the endocytic pathway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20235611      PMCID: PMC3593351          DOI: 10.1021/jm100135g

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  19 in total

1.  Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain.

Authors:  V J Hruby; R S Agnes; P Davis; S-W Ma; Y S Lee; T W Vanderah; J Lai; F Porreca
Journal:  Life Sci       Date:  2003-06-27       Impact factor: 5.037

2.  A bivalent ligand (KDAN-18) containing delta-antagonist and kappa-agonist pharmacophores bridges delta2 and kappa1 opioid receptor phenotypes.

Authors:  David J Daniels; Amol Kulkarni; Zhihua Xie; Rashmi G Bhushan; Philip S Portoghese
Journal:  J Med Chem       Date:  2005-03-24       Impact factor: 7.446

3.  Relationship between native and recombinant cholecystokinin receptors: role of differential glycosylation.

Authors:  E M Hadac; D V Ghanekar; E L Holicky; D I Pinon; R W Dougherty; L J Miller
Journal:  Pancreas       Date:  1996-08       Impact factor: 3.327

4.  Antagonist-stimulated internalization of the G protein-coupled cholecystokinin receptor.

Authors:  B F Roettger; D Ghanekar; R Rao; C Toledo; J Yingling; D Pinon; L J Miller
Journal:  Mol Pharmacol       Date:  1997-03       Impact factor: 4.436

5.  Cholecystokinin-B receptor antagonists attenuate morphine dependence and withdrawal in rats.

Authors:  L Lu; M Huang; Z Liu; L Ma
Journal:  Neuroreport       Date:  2000-03-20       Impact factor: 1.837

6.  Evidence for the neuropeptide cholecystokinin as an antagonist of opiate analgesia.

Authors:  P L Faris; B R Komisaruk; L R Watkins; D J Mayer
Journal:  Science       Date:  1983-01-21       Impact factor: 47.728

7.  Synthesis and in vitro characterization of radioiodinatable benzodiazepines selective for type 1 and type 2 cholecystokinin receptors.

Authors:  Eyup Akgün; Meike Körner; Fan Gao; Kaleeckal G Harikumar; Beatrice Waser; Jean Claude Reubi; Philip S Portoghese; Laurence J Miller
Journal:  J Med Chem       Date:  2009-04-09       Impact factor: 7.446

8.  Use of N,O-bis-Fmoc-D-Tyr-ONSu for introduction of an oxidative iodination site into cholecystokinin family peptides.

Authors:  S P Powers; D I Pinon; L J Miller
Journal:  Int J Pept Protein Res       Date:  1988-05

9.  Narcotic antagonistic potency of bivalent ligands which contain beta-naltrexamine. Evidence for bridging between proximal recognition sites.

Authors:  M Erez; A E Takemori; P S Portoghese
Journal:  J Med Chem       Date:  1982-07       Impact factor: 7.446

10.  Dual pathways of internalization of the cholecystokinin receptor.

Authors:  B F Roettger; R U Rentsch; D Pinon; E Holicky; E Hadac; J M Larkin; L J Miller
Journal:  J Cell Biol       Date:  1995-03       Impact factor: 10.539

View more
  10 in total

1.  Development and in vitro characterization of a novel bifunctional μ-agonist/δ-antagonist opioid tetrapeptide.

Authors:  Lauren C Purington; Katarzyna Sobczyk-Kojiro; Irina D Pogozheva; John R Traynor; Henry I Mosberg
Journal:  ACS Chem Biol       Date:  2011-10-11       Impact factor: 5.100

2.  Ligand-induced internalization of the type 1 cholecystokinin receptor independent of recognized signaling activity.

Authors:  Erin E Cawston; Kaleeckal G Harikumar; Laurence J Miller
Journal:  Am J Physiol Cell Physiol       Date:  2011-11-02       Impact factor: 4.249

3.  Opioid bifunctional ligands from morphine and the opioid pharmacophore Dmt-Tic.

Authors:  Gianfranco Balboni; Severo Salvadori; Ewa D Marczak; Brian I Knapp; Jean M Bidlack; Lawrence H Lazarus; Xuemei Peng; Yu Gui Si; John L Neumeyer
Journal:  Eur J Med Chem       Date:  2010-12-08       Impact factor: 6.514

4.  A Direct in Vivo Comparison of the Melanocortin Monovalent Agonist Ac-His-DPhe-Arg-Trp-NH2 versus the Bivalent Agonist Ac-His-DPhe-Arg-Trp-PEDG20-His-DPhe-Arg-Trp-NH2: A Bivalent Advantage.

Authors:  Cody J Lensing; Danielle N Adank; Stacey L Wilber; Katie T Freeman; Sathya M Schnell; Robert C Speth; Adam T Zarth; Carrie Haskell-Luevano
Journal:  ACS Chem Neurosci       Date:  2017-02-16       Impact factor: 4.418

5.  Design and synthesis of a bivalent ligand to explore the putative heterodimerization of the mu opioid receptor and the chemokine receptor CCR5.

Authors:  Yunyun Yuan; Christopher K Arnatt; Guo Li; Kendra M Haney; Derong Ding; Joanna C Jacob; Dana E Selley; Yan Zhang
Journal:  Org Biomol Chem       Date:  2012-02-22       Impact factor: 3.876

Review 6.  CCK2 receptors in chronic pain.

Authors:  Justin E LaVigne; Sascha R A Alles
Journal:  Neurobiol Pain       Date:  2022-05-05

7.  An in Vitro and in Vivo Investigation of Bivalent Ligands That Display Preferential Binding and Functional Activity for Different Melanocortin Receptor Homodimers.

Authors:  Cody J Lensing; Katie T Freeman; Sathya M Schnell; Danielle N Adank; Robert C Speth; Carrie Haskell-Luevano
Journal:  J Med Chem       Date:  2016-03-29       Impact factor: 7.446

8.  Synergism between a serotonin 5-HT2A receptor (5-HT2AR) antagonist and 5-HT2CR agonist suggests new pharmacotherapeutics for cocaine addiction.

Authors:  Kathryn A Cunningham; Noelle C Anastasio; Robert G Fox; Sonja J Stutz; Marcy J Bubar; Sarah E Swinford; Cheryl S Watson; Scott R Gilbertson; Kenner C Rice; Sharon Rosenzweig-Lipson; F Gerard Moeller
Journal:  ACS Chem Neurosci       Date:  2012-08-11       Impact factor: 4.418

9.  Bivalent ligands that target μ opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance.

Authors:  Morgan Le Naour; Eyup Akgün; Ajay Yekkirala; Mary M Lunzer; Mike D Powers; Alexander E Kalyuzhny; Philip S Portoghese
Journal:  J Med Chem       Date:  2013-06-20       Impact factor: 7.446

10.  Bivalent Ligand UDCA-LPE Inhibits Pro-Fibrogenic Integrin Signalling by Inducing Lipid Raft-Mediated Internalization.

Authors:  Jie Su; Hongying Gan-Schreier; Benjamin Goeppert; Walee Chamulitrat; Wolfgang Stremmel; Anita Pathil
Journal:  Int J Mol Sci       Date:  2018-10-20       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.